These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2541225)

  • 41. Human rhinovirus capsid dynamics is controlled by canyon flexibility.
    Reisdorph N; Thomas JJ; Katpally U; Chase E; Harris K; Siuzdak G; Smith TJ
    Virology; 2003 Sep; 314(1):34-44. PubMed ID: 14517058
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human rhinovirus 14 complexed with antiviral compound R 61837.
    Chapman MS; Minor I; Rossmann MG; Diana GD; Andries K
    J Mol Biol; 1991 Feb; 217(3):455-63. PubMed ID: 1847215
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound.
    Heinz BA; Rueckert RR; Shepard DA; Dutko FJ; McKinlay MA; Fancher M; Rossmann MG; Badger J; Smith TJ
    J Virol; 1989 Jun; 63(6):2476-85. PubMed ID: 2542566
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The structure of human rhinovirus 16.
    Oliveira MA; Zhao R; Lee WM; Kremer MJ; Minor I; Rueckert RR; Diana GD; Pevear DC; Dutko FJ; McKinlay MA
    Structure; 1993 Sep; 1(1):51-68. PubMed ID: 7915182
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders.
    Morley A; Tomkinson N; Cook A; MacDonald C; Weaver R; King S; Jenkinson L; Unitt J; McCrae C; Phillips T
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6031-5. PubMed ID: 21907579
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanical stiffening of human rhinovirus by cavity-filling antiviral drugs.
    Valbuena A; Rodríguez-Huete A; Mateu MG
    Nanoscale; 2018 Jan; 10(3):1440-1452. PubMed ID: 29302674
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Human Rhinovirus Inhibition Through Capsid "Canyon" Perturbation: Structural Insights into The Role of a Novel Benzothiophene Derivative.
    Agoni C; Ramharack P; Munsamy G; Soliman MES
    Cell Biochem Biophys; 2020 Mar; 78(1):3-13. PubMed ID: 31834576
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Investigation on QSAR and binding mode of a new class of human rhinovirus-14 inhibitors by CoMFA and docking experiments.
    Artico M; Botta M; Corelli F; Mai A; Massa S; Ragno R
    Bioorg Med Chem; 1996 Oct; 4(10):1715-24. PubMed ID: 8931942
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-distance correlations of rhinovirus capsid dynamics contribute to uncoating and antiviral activity.
    Roy A; Post CB
    Proc Natl Acad Sci U S A; 2012 Apr; 109(14):5271-6. PubMed ID: 22440750
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antiviral agent blocks breathing of the common cold virus.
    Lewis JK; Bothner B; Smith TJ; Siuzdak G
    Proc Natl Acad Sci U S A; 1998 Jun; 95(12):6774-8. PubMed ID: 9618488
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacophore-based design, synthesis, and biological evaluation of novel chloro-pyridazine piperazines as human rhinovirus (HRV-3) inhibitors.
    Wang H; Xiao J; Gao D; Zhang X; Yan H; Gong Z; Sun T; Li S
    Bioorg Med Chem Lett; 2011 Feb; 21(3):1057-9. PubMed ID: 21215622
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design, synthesis and in vitro evaluation of novel chroman-4-one, chroman, and 2H-chromene derivatives as human rhinovirus capsid-binding inhibitors.
    Conti C; Proietti Monaco L; Desideri N
    Bioorg Med Chem; 2011 Dec; 19(24):7357-64. PubMed ID: 22088306
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular mechanism of rhinovirus escape from the Pyrazolo[3,4-d]pyrimidine capsid-binding inhibitor OBR-5-340 via mutations distant from the binding pocket: Derivatives that brake resistance.
    Richter M; Döring K; Blaas D; Riabova O; Khrenova M; Kazakova E; Egorova A; Makarov V; Schmidtke M
    Antiviral Res; 2024 Feb; 222():105810. PubMed ID: 38244889
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Investigation of shape variations in the antibody binding site by molecular dynamics computer simulation.
    de la Cruz X; Mark AE; Tormo J; Fita I; van Gunsteren WF
    J Mol Biol; 1994 Mar; 236(4):1186-95. PubMed ID: 8120895
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating.
    Smith TJ; Kremer MJ; Luo M; Vriend G; Arnold E; Kamer G; Rossmann MG; McKinlay MA; Diana GD; Otto MJ
    Science; 1986 Sep; 233(4770):1286-93. PubMed ID: 3018924
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Selection of high affinity RNA ligands to a synthetic peptide of human rhinovirus 14 coat protein.
    De Beuckelaer A; Fürste JP
    Nucleic Acids Symp Ser; 1995; (33):23. PubMed ID: 8643380
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enantiomeric effects of homologues of disoxaril on the inhibitory activity against human rhinovirus-14.
    Diana GD; Otto MJ; Treasurywala AM; McKinlay MA; Oglesby RC; Maliski EG; Rossmann MG; Smith TJ
    J Med Chem; 1988 Mar; 31(3):540-4. PubMed ID: 2831362
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Study of the parameters of binding of R 61837 to human rhinovirus 9 and immunobiochemical evidence of capsid-stabilizing activity of the compound.
    Moeremans M; De Raeymaeker M; Daneels G; De Brabander M; Aerts F; Janssen C; Andries K
    Antimicrob Agents Chemother; 1992 Feb; 36(2):417-24. PubMed ID: 1318682
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies.
    Dragovich PS; Webber SE; Babine RE; Fuhrman SA; Patick AK; Matthews DA; Lee CA; Reich SH; Prins TJ; Marakovits JT; Littlefield ES; Zhou R; Tikhe J; Ford CE; Wallace MB; Meador JW; Ferre RA; Brown EL; Binford SL; Harr JE; DeLisle DM; Worland ST
    J Med Chem; 1998 Jul; 41(15):2806-18. PubMed ID: 9667970
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SCH 38057: a picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating.
    Rozhon E; Cox S; Buontempo P; O'Connell J; Slater W; De Martino J; Schwartz J; Miller G; Arnold E; Zhang A
    Antiviral Res; 1993 May; 21(1):15-35. PubMed ID: 8391247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.